Stockreport

CEL-SCI Corporation Reports First Quarter Fiscal 2024 Financial Results [Yahoo! Finance]

Cel-Sci Corporation  (CVM) 
NASDAQ:AMEX Investor Relations: cel-sci.com/investor_relations.html
PDF Clinical and Corporate Developments include: CEL-SCI identified the target head and neck cancer patient population for Multikine ® (Leukocyte Interleukin, Injection)* [Read more]